{
  "symbol": "GOVXW",
  "company_name": "Geovax Labs Inc WT",
  "ir_website": "https://www.geovax.com/investors/",
  "structured_data": [
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "News",
          "url": "https://www.geovax.com/investors/press-releases",
          "content": "Accessibility Tools\n\n  * Invert colors\n  * Monochrome\n  * Dark contrast\n  * Light contrast\n  * Low saturation\n  * High saturation\n  * Highlight links\n  * Highlight headings\n  * Screen reader\n  * Read mode\n  * Content scaling 100%\n  * Font size 100%\n  * Line height 100%\n  * Letter spacing 100%\n\n\n\n  * [(678) 384-7220](tel:\\(678\\)384-7220)\n  * info@geovax.com\n\n\n  * [](https://twitter.com/geovax_news)\n  * [](https://www.youtube.com/channel/UC8n5AVvUdjFgAgGde_mA_rg)\n  * [](https://www.linkedin.com/company/2124638)\n\n\n\n[![GeoVax](/images/GeoVax_logo-bright-blue-v2-315px.png)](/index.php \"GeoVax\")\n\n[](#)\n\n  * [About Us](/about-geovax \"About GeoVax\")\n\n    * [Company](/about-geovax/company \"GeoVax Company\")\n    * [Leadership](/about-geovax/leadership \"Leadership\")\n    * [Board of Directors & Corporate Advisors](/about-geovax/board-of-directors-corporate-advisors \"Board of Directors\")\n    * [Scientific Advisory Board](/about-geovax/scientific-advisory-board \"Scientific Advisory Board\")\n    * [Collaborators](/about-geovax/collaborators \"Collaborators\")\n\n  * [Technology](/technology \"Our Technology\")\n\n    * [MVA Technology Overview](/technology/mva-technology-overview \"MVA-VLP Technology Overview\")\n    * [Gedeptin® Technology Overview](/technology/gedeptin-technology-overview \"Gedeptin® Technology Overview\")\n    * [Publications](/technology/publications \"GeoVax Publications\")\n\n  * [Pipeline](/technology-pipeline \"GeoVax Technology Pipeline\")\n\n    * [Pipeline Summary](/technology-pipeline/pipeline-summary \"Pipeline Summary\")\n    * [Oncology](/technology-pipeline/oncology \"GeoVax Immuno-Oncology Programs\")\n    * [Infectious Diseases](/technology-pipeline/infectious-diseases \"GeoVax Infectious Disease Programs\")\n\n  * [Clinical Trials](/clinical-trial \"Clinical Trials\")\n  * [Investors](/investors \"Investors\")\n\n    * [Corporate Profile](/investors/corporate-profile \"Corporate Profile\")\n    * [Press Releases](/investors/press-releases)\n    * [Media](/investors/media)\n    * [Events & Presentations](/investors/events-presentations \"GeoVax Events\")\n    * [SEC Filings](/investors/sec-filings-securities-and-exchange \"GeoVax SEC Filings\")\n    * [GeoVax Stock Information](/investors/stock-information \"GOVX Stock Information\")\n    * [Corporate Governance](/investors/corporate-governance \"Corporate Governance\")\n    * [Analyst Coverage](/investors/analyst-coverage \"Analyst Coverage\")\n    * [Investor FAQ's](/investors/investor-faq-s \"Investor FAQ's\")\n\n  * [Careers](/careers \"Careers with GeoVax\")\n  * [Contact](/contact-us \"Contact GeoVax\")\n\n\n\n## Press Releases\n\n[ November 26 2024 ](/investors/press-releases/geovax-to-present-at-the-noble-capital-markets-twentieth-annual-emerging-growth-equity-conference)\n\n#  [ GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference ](/investors/press-releases/geovax-to-present-at-the-noble-capital-markets-twentieth-annual-emerging-growth-equity-conference)\n\n[ November 19 2024 ](/investors/press-releases/geovax-announces-positive-interim-data-review-for-phase-2-clinical-trial-of-covid-19-vaccine-booster-in-patients-with-chronic-lymphocytic-leukemia)\n\n#  [ GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia ](/investors/press-releases/geovax-announces-positive-interim-data-review-for-phase-2-clinical-trial-of-covid-19-vaccine-booster-in-patients-with-chronic-lymphocytic-leukemia)\n\n[ November 12 2024 ](/investors/press-releases/geovax-reports-third-quarter-2024-financial-results-and-provides-business-update)\n\n#  [ GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update ](/investors/press-releases/geovax-reports-third-quarter-2024-financial-results-and-provides-business-update)\n\n[ November 05 2024 ](/investors/press-releases/geovax-to-report-third-quarter-2024-financial-results-and-provide-corporate-update-on-november-12-2024)\n\n#  [ GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024 ](/investors/press-releases/geovax-to-report-third-quarter-2024-financial-results-and-provide-corporate-update-on-november-12-2024)\n\n[ October 02 2024 ](/investors/press-releases/geovax-to-participate-in-the-3rd-annual-roth-healthcare-opportunities-conference)\n\n#  [ GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference ](/investors/press-releases/geovax-to-participate-in-the-3rd-annual-roth-healthcare-opportunities-conference)\n\n[ September 03 2024 ](/investors/press-releases/geovax-to-participate-in-upcoming-investor-conferences-in-september)\n\n#  [ GeoVax to Participate in Upcoming Investor Conferences in September ](/investors/press-releases/geovax-to-participate-in-upcoming-investor-conferences-in-september)\n\n[ August 28 2024 ](/investors/press-releases/geovax-to-raise-approximately-5-0-million-of-gross-proceeds-in-offering-priced-at-the-market)\n\n#  [ GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market ](/investors/press-releases/geovax-to-raise-approximately-5-0-million-of-gross-proceeds-in-offering-priced-at-the-market)\n\n[ August 21 2024 ](/investors/press-releases/registration-is-now-open-for-tribe-public-s-webinar-event-now-is-not-the-time-to-monkey-pox-around-featuring-geovax-lab-s-ceo)\n\n#  [ Registration Is Now Open for Tribe Public’s Webinar Event \"Now Is Not the Time to Monkey(pox) Around\" Featuring GeoVax Lab’s CEO ](/investors/press-releases/registration-is-now-open-for-tribe-public-s-webinar-event-now-is-not-the-time-to-monkey-pox-around-featuring-geovax-lab-s-ceo)\n\n[ August 20 2024 ](/investors/press-releases/geovax-to-raise-approximately-8-5-million-of-gross-proceeds-in-offering-priced-above-the-market)\n\n#  [ GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market ](/investors/press-releases/geovax-to-raise-approximately-8-5-million-of-gross-proceeds-in-offering-priced-above-the-market)\n\n[ August 15 2024 ](/investors/press-releases/geovax-to-present-at-the-emerging-growth-conference-on-august-21-2024)\n\n#  [ GeoVax to Present at the Emerging Growth Conference on August 21, 2024 ](/investors/press-releases/geovax-to-present-at-the-emerging-growth-conference-on-august-21-2024)\n\n[ August 08 2024 ](/investors/press-releases/geovax-appoints-teresa-lambe-acclaimed-professor-of-vaccinology-and-immunology-at-the-oxford-vaccine-group-to-its-scientific-advisory-board)\n\n#  [ GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board ](/investors/press-releases/geovax-appoints-teresa-lambe-acclaimed-professor-of-vaccinology-and-immunology-at-the-oxford-vaccine-group-to-its-scientific-advisory-board)\n\n[ August 06 2024 ](/investors/press-releases/geovax-reports-second-quarter-2024-financial-results-and-provides-business-update)\n\n#  [ GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update ](/investors/press-releases/geovax-reports-second-quarter-2024-financial-results-and-provides-business-update)\n\n[ July 31 2024 ](/investors/press-releases/geovax-announces-phase-2-plans-for-gedeptin-cancer-therapy-following-clinical-advisory-committee-review)\n\n#  [ GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review ](/investors/press-releases/geovax-announces-phase-2-plans-for-gedeptin-cancer-therapy-following-clinical-advisory-committee-review)\n\n[ July 30 2024 ](/investors/press-releases/geovax-to-report-second-quarter-2024-financial-results-and-provide-corporate-update-on-august-6-2024)\n\n#  [ GeoVax to Report Second Quarter 2024 Financial Results and Provide Corporate Update on August 6, 2024 ](/investors/press-releases/geovax-to-report-second-quarter-2024-financial-results-and-provide-corporate-update-on-august-6-2024)\n\n[ July 16 2024 ](/investors/press-releases/geovax-to-present-at-the-emerging-growth-conference-on-july-18-2024)\n\n#  [ GeoVax to Present at the Emerging Growth Conference on July 18, 2024 ](/investors/press-releases/geovax-to-present-at-the-emerging-growth-conference-on-july-18-2024)\n\n[ July 11 2024 ](/investors/press-releases/geovax-to-raise-approximately-3-1-million-of-gross-proceeds-in-offering-priced-at-the-market)\n\n#  [ GeoVax to Raise Approximately $3.1 Million of Gross Proceeds in Offering Priced At-the-Market ](/investors/press-releases/geovax-to-raise-approximately-3-1-million-of-gross-proceeds-in-offering-priced-at-the-market)\n\n[ July 09 2024 ](/investors/press-releases/geovax-provides-first-half-2024-business-update)\n\n#  [ GeoVax Provides First Half 2024 Business Update ](/investors/press-releases/geovax-provides-first-half-2024-business-update)\n\n[ June 27 2024 ](/investors/press-releases/geovax-partners-with-allucent-to-conduct-phase-2b-clinical-study-of-next-generation-covid-19-vaccine-candidate-with-funding-from-barda)\n\n#  [ GeoVax Partners with Allucent to Conduct Phase 2b Clinical Study of Next-Generation COVID-19 Vaccine Candidate with Funding from BARDA ](/investors/press-releases/geovax-partners-with-allucent-to-conduct-phase-2b-clinical-study-of-next-generation-covid-19-vaccine-candidate-with-funding-from-barda)\n\n[ June 18 2024 ](/investors/press-releases/geovax-receives-barda-project-nextgen-award-to-conduct-phase-2b-clinical-study-evaluating-the-company-s-next-generation-covid-19-vaccine-candidate-geo-cm04s1)\n\n#  [ GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company’s Next-Generation COVID-19 Vaccine Candidate, GEO-CM04S1 ](/investors/press-releases/geovax-receives-barda-project-nextgen-award-to-conduct-phase-2b-clinical-study-evaluating-the-company-s-next-generation-covid-19-vaccine-candidate-geo-cm04s1)\n\n[ May 29 2024 ](/investors/press-releases/geovax-to-present-at-bio-international-convention-2024)\n\n#  [ GeoVax to Present at BIO International Convention 2024 ](/investors/press-releases/geovax-to-present-at-bio-international-convention-2024)\n\n[ May 17 2024 ](/investors/press-releases/geovax-to-raise-approximately-1-3-million-of-gross-proceeds-in-offering-priced-at-the-market)\n\n#  [ GeoVax to Raise Approximately $1.3 Million of Gross Proceeds in Offering Priced At-the-Market ](/investors/press-releases/geovax-to-raise-approximately-1-3-million-of-gross-proceeds-in-offering-priced-at-the-market)\n\n[ May 14 2024 ](/investors/press-releases/geovax-reports-first-quarter-2024-financial-results-and-provides-business-update)\n\n#  [ GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update ](/investors/press-releases/geovax-reports-first-quarter-2024-financial-results-and-provides-business-update)\n\n[ May 07 2024 ](/investors/press-releases/geovax-to-report-first-quarter-2024-financial-results-and-provide-corporate-update-on-may-14-2024)\n\n#  [ GeoVax to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024 ](/investors/press-releases/geovax-to-report-first-quarter-2024-financial-results-and-provide-corporate-update-on-may-14-2024)\n\n[ April 04 2024 ](/investors/press-releases/geovax-presents-data-on-geo-cm04s1-a-next-generation-covid-19-vaccine)\n\n#  [ GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine ](/investors/press-releases/geovax-presents-data-on-geo-cm04s1-a-next-generation-covid-19-vaccine)\n\n[ March 28 2024 ](/investors/press-releases/geovax-to-present-data-on-geo-cm04s1-a-next-generation-covid-19-vaccine-at-the-world-vaccine-congress)\n\n#  [ GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress ](/investors/press-releases/geovax-to-present-data-on-geo-cm04s1-a-next-generation-covid-19-vaccine-at-the-world-vaccine-congress)\n\n[ March 12 2024 ](/investors/press-releases/geovax-to-present-at-the-36th-annual-roth-conference)\n\n#  [ GeoVax to Present at the 36th Annual Roth Conference ](/investors/press-releases/geovax-to-present-at-the-36th-annual-roth-conference)\n\n[ March 06 2024 ](/investors/press-releases/geovax-achieves-milestone-in-transition-to-commercially-validated-manufacturing-system)\n\n#  [ GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System ](/investors/press-releases/geovax-achieves-milestone-in-transition-to-commercially-validated-manufacturing-system)\n\n[ February 29 2024 ](/investors/press-releases/geovax-reports-2023-year-end-financial-results-and-provides-business-update)\n\n#  [ GeoVax Reports 2023 Year-End Financial Results and Provides Business Update ](/investors/press-releases/geovax-reports-2023-year-end-financial-results-and-provides-business-update)\n\n[ February 22 2024 ](/investors/press-releases/geovax-to-report-2023-financial-results-and-provide-corporate-update-on-february-29-2024)\n\n#  [ GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 ](/investors/press-releases/geovax-to-report-2023-financial-results-and-provide-corporate-update-on-february-29-2024)\n\n[ February 19 2024 ](/investors/press-releases/geovax-to-present-at-the-2024-bio-ceo-investor-conference)\n\n#  [ GeoVax to Present at the 2024 BIO CEO & Investor Conference ](/investors/press-releases/geovax-to-present-at-the-2024-bio-ceo-investor-conference)\n\n[ February 13 2024 ](/investors/press-releases/geovax-announces-multiple-patent-issuances-and-allowances)\n\n#  [ GeoVax Announces Multiple Patent Issuances and Allowances ](/investors/press-releases/geovax-announces-multiple-patent-issuances-and-allowances)\n\n[ February 06 2024 ](/investors/press-releases/geovax-reports-positive-interim-data-from-phase-2-clinical-trial-of-geo-cm04s1-as-a-universal-covid-19-vaccine-booster)\n\n#  [ GeoVax Reports Positive Interim Data from Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster ](/investors/press-releases/geovax-reports-positive-interim-data-from-phase-2-clinical-trial-of-geo-cm04s1-as-a-universal-covid-19-vaccine-booster)\n\n[ January 29 2024 ](/investors/press-releases/geovax-announces-1-for-15-reverse-stock-split-to-regain-compliance-with-nasdaq-minimum-bid-requirement)\n\n#  [ GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement ](/investors/press-releases/geovax-announces-1-for-15-reverse-stock-split-to-regain-compliance-with-nasdaq-minimum-bid-requirement)\n\n[ January 08 2024 ](/investors/press-releases/geovax-appoints-dr-marc-pipas-as-executive-medical-director-oncology)\n\n#  [ GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology ](/investors/press-releases/geovax-appoints-dr-marc-pipas-as-executive-medical-director-oncology)\n\n[ January 04 2024 ](/investors/press-releases/geovax-announces-gedeptin-patient-enrollment-closure-for-phase-1-2-clinical-trial-among-advanced-head-and-neck-cancer-patients)\n\n#  [ GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients ](/investors/press-releases/geovax-announces-gedeptin-patient-enrollment-closure-for-phase-1-2-clinical-trial-among-advanced-head-and-neck-cancer-patients)\n\n[ January 03 2024 ](/investors/press-releases/geovax-announces-issuance-of-malaria-vaccine-patent-2)\n\n#  [ GeoVax Announces Issuance of Malaria Vaccine Patent ](/investors/press-releases/geovax-announces-issuance-of-malaria-vaccine-patent-2)\n\n[ December 27 2023 ](/investors/press-releases/geovax-to-present-at-biotech-showcase-during-j-p-morgan-healthcare-week-2024)\n\n#  [ GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024 ](/investors/press-releases/geovax-to-present-at-biotech-showcase-during-j-p-morgan-healthcare-week-2024)\n\n[ December 19 2023 ](/investors/press-releases/geovax-expands-rights-under-nih-covid-19-license-to-include-mpox-and-smallpox)\n\n#  [ GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox ](/investors/press-releases/geovax-expands-rights-under-nih-covid-19-license-to-include-mpox-and-smallpox)\n\n[ November 30 2023 ](/investors/press-releases/geovax-hemorrhagic-fever-vaccine-data-presented-at-world-vaccine-congress)\n\n#  [ GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress ](/investors/press-releases/geovax-hemorrhagic-fever-vaccine-data-presented-at-world-vaccine-congress)\n\n[ November 29 2023 ](/investors/press-releases/geovax-to-participate-in-upcoming-december-investor-events)\n\n#  [ GeoVax to Participate in Upcoming December Investor Events ](/investors/press-releases/geovax-to-participate-in-upcoming-december-investor-events)\n\n[ November 28 2023 ](/investors/press-releases/geovax-covid-19-vaccine-clinical-data-presented-at-world-vaccine-congress)\n\n#  [ GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress ](/investors/press-releases/geovax-covid-19-vaccine-clinical-data-presented-at-world-vaccine-congress)\n\n[ November 14 2023 ](/investors/press-releases/progress-on-geovax-s-universal-coronavirus-vaccine-candidate-geo-cm02-presented-at-vaccines-summit-2023)\n\n#  [ Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 ](/investors/press-releases/progress-on-geovax-s-universal-coronavirus-vaccine-candidate-geo-cm02-presented-at-vaccines-summit-2023)\n\n[ November 08 2023 ](/investors/press-releases/geovax-reports-third-quarter-2023-financial-results-and-provides-business-update)\n\n#  [ GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update ](/investors/press-releases/geovax-reports-third-quarter-2023-financial-results-and-provides-business-update)\n\n[ October 31 2023 ](/investors/press-releases/geovax-to-report-third-quarter-2023-financial-results-and-provide-corporate-update-on-november-8-2023)\n\n#  [ GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 ](/investors/press-releases/geovax-to-report-third-quarter-2023-financial-results-and-provide-corporate-update-on-november-8-2023)\n\n[ October 30 2023 ](/investors/press-releases/geovax-commences-site-expansion-for-phase-2-trial-of-next-generation-covid-19-vaccine)\n\n#  [ GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine ](/investors/press-releases/geovax-commences-site-expansion-for-phase-2-trial-of-next-generation-covid-19-vaccine)\n\n[ October 25 2023 ](/investors/press-releases/geovax-to-participate-in-upcoming-november-investor-and-industry-events)\n\n#  [ GeoVax to Participate in Upcoming November Investor and Industry Events ](/investors/press-releases/geovax-to-participate-in-upcoming-november-investor-and-industry-events)\n\n[ October 24 2023 ](/investors/press-releases/geovax-update-clinical-and-operational-progress-toward-transformative-opportunities)\n\n#  [ GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities ](/investors/press-releases/geovax-update-clinical-and-operational-progress-toward-transformative-opportunities)\n\n[ October 09 2023 ](/investors/press-releases/geovax-receives-notice-of-allowance-for-marburg-vaccine-patent)\n\n#  [ GeoVax Receives Notice of Allowance for Marburg Vaccine Patent ](/investors/press-releases/geovax-receives-notice-of-allowance-for-marburg-vaccine-patent)\n\n[ October 05 2023 ](/investors/press-releases/geovax-receives-notice-of-allowance-for-hiv-vaccine-patent)\n\n#  [ GeoVax Receives Notice of Allowance for HIV Vaccine Patent ](/investors/press-releases/geovax-receives-notice-of-allowance-for-hiv-vaccine-patent)\n\n[ September 27 2023 ](/investors/press-releases/geovax-to-participate-in-upcoming-october-investor-and-industry-events)\n\n#  [ GeoVax to Participate in Upcoming October Investor and Industry Events ](/investors/press-releases/geovax-to-participate-in-upcoming-october-investor-and-industry-events)\n\n[ September 26 2023 ](/investors/press-releases/geovax-secures-multi-product-license-for-probiogen-s-age1-cr-pix-suspension-cell-line-to-bolster-mva-based-vaccine-development)\n\n#  [ GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development ](/investors/press-releases/geovax-secures-multi-product-license-for-probiogen-s-age1-cr-pix-suspension-cell-line-to-bolster-mva-based-vaccine-development)\n\n[ September 20 2023 ](/investors/press-releases/geovax-next-generation-covid-19-vaccine-data-presented-at-keystone-symposia-conference)\n\n#  [ GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference ](/investors/press-releases/geovax-next-generation-covid-19-vaccine-data-presented-at-keystone-symposia-conference)\n\n[ September 19 2023 ](/investors/press-releases/geovax-next-generation-covid-19-vaccine-demonstrates-potent-antibody-and-cellular-immunity-in-immunocompromised-patients)\n\n#  [ GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients ](/investors/press-releases/geovax-next-generation-covid-19-vaccine-demonstrates-potent-antibody-and-cellular-immunity-in-immunocompromised-patients)\n\n[ September 12 2023 ](/investors/press-releases/geovax-presents-corporate-update-at-the-h-c-wainwright-25th-annual-global-investment-conference-2)\n\n#  [ GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference ](/investors/press-releases/geovax-presents-corporate-update-at-the-h-c-wainwright-25th-annual-global-investment-conference-2)\n\n[ September 11 2023 ](/investors/press-releases/geovax-completes-enrollment-of-phase-2-trial-for-next-generation-covid-19-vaccine-booster)\n\n#  [ GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster ](/investors/press-releases/geovax-completes-enrollment-of-phase-2-trial-for-next-generation-covid-19-vaccine-booster)\n\n[ August 31 2023 ](/investors/press-releases/geovax-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference)\n\n#  [ GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference ](/investors/press-releases/geovax-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference)\n\n[ August 29 2023 ](/investors/press-releases/geovax-to-present-at-the-emerging-growth-conference-on-september-6-2023)\n\n#  [ GeoVax to Present at the Emerging Growth Conference on September 6, 2023 ](/investors/press-releases/geovax-to-present-at-the-emerging-growth-conference-on-september-6-2023)\n\n[ August 28 2023 ](/investors/press-releases/geovax-receives-notice-of-allowance-for-malaria-vaccine-patent-2)\n\n#  [ GeoVax Receives Notice of Allowance for Malaria Vaccine Patent ](/investors/press-releases/geovax-receives-notice-of-allowance-for-malaria-vaccine-patent-2)\n\n[ August 10 2023 ](/investors/press-releases/geovax-announces-first-patients-vaccinated-in-phase-2-clinical-trial-of-covid-19-vaccine-booster-in-patients-with-chronic-lymphocytic-leukemia)\n\n#  [ GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia  ](/investors/press-releases/geovax-announces-first-patients-vaccinated-in-phase-2-clinical-trial-of-covid-19-vaccine-booster-in-patients-with-chronic-lymphocytic-leukemia)\n\n[ August 09 2023 ](/investors/press-releases/geovax-reports-2023-second-quarter-financial-results-and-provides-corporate-update)\n\n#  [ GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update ](/investors/press-releases/geovax-reports-2023-second-quarter-financial-results-and-provides-corporate-update)\n\n[ July 26 2023 ](/investors/press-releases/geovax-to-report-second-quarter-2023-financial-results-and-provide-corporate-update-on-wednesday-august-9-2023)\n\n#  [ GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 ](/investors/press-releases/geovax-to-report-second-quarter-2023-financial-results-and-provide-corporate-update-on-wednesday-august-9-2023)\n\n[ July 24 2023 ](/investors/press-releases/geovax-announces-issuance-of-ebola-vaccine-patent)\n\n#  [ GeoVax Announces Issuance of Ebola Vaccine Patent ](/investors/press-releases/geovax-announces-issuance-of-ebola-vaccine-patent)\n\n[ July 20 2023 ](/investors/press-releases/geovax-announces-initiation-of-phase-2-clinical-trial-of-covid-19-vaccine-booster-in-patients-with-chronic-lymphocytic-leukemia)\n\n#  [ GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia  ](/investors/press-releases/geovax-announces-initiation-of-phase-2-clinical-trial-of-covid-19-vaccine-booster-in-patients-with-chronic-lymphocytic-leukemia)\n\n[ July 10 2023 ](/investors/press-releases/geovax-presents-gedeptin-clinical-data-at-the-aacr-ahns-head-and-neck-cancer-conference)\n\n#  [ GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference ](/investors/press-releases/geovax-presents-gedeptin-clinical-data-at-the-aacr-ahns-head-and-neck-cancer-conference)\n\n[ June 28 2023 ](/investors/press-releases/geovax-announces-gedeptin-presentation-at-the-aacr-ahns-head-and-neck-cancer-conference)\n\n#  [ GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference ](/investors/press-releases/geovax-announces-gedeptin-presentation-at-the-aacr-ahns-head-and-neck-cancer-conference)\n\n[ June 27 2023 ](/investors/press-releases/geovax-universal-coronavirus-vaccine-design-development-approach-published-in-vaccine-insights)\n\n#  [ GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights ](/investors/press-releases/geovax-universal-coronavirus-vaccine-design-development-approach-published-in-vaccine-insights)\n\n[ May 31 2023 ](/investors/press-releases/geovax-partners-with-abl-to-advance-cgmp-production-of-vaccine-candidates)\n\n#  [ GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates  ](/investors/press-releases/geovax-partners-with-abl-to-advance-cgmp-production-of-vaccine-candidates)\n\n[ May 25 2023 ](/investors/press-releases/geovax-to-participate-in-upcoming-industry-meetings)\n\n#  [ GeoVax to Participate in Upcoming Industry Meetings ](/investors/press-releases/geovax-to-participate-in-upcoming-industry-meetings)\n\n[ May 24 2023 ](/investors/press-releases/geovax-s-next-generation-covid-19-vaccine-shows-high-immunogenicity-in-immunocompromised-patients)\n\n#  [ GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients ](/investors/press-releases/geovax-s-next-generation-covid-19-vaccine-shows-high-immunogenicity-in-immunocompromised-patients)\n\n[ May 15 2023 ](/investors/press-releases/geovax-next-generation-covid-19-vaccine-data-to-be-presented-at-two-upcoming-scientific-meetings)\n\n#  [ GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings ](/investors/press-releases/geovax-next-generation-covid-19-vaccine-data-to-be-presented-at-two-upcoming-scientific-meetings)\n\n[ May 09 2023 ](/investors/press-releases/geovax-labs-to-participate-in-a-g-p-s-virtual-healthcare-conference)\n\n#  [ GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference ](/investors/press-releases/geovax-labs-to-participate-in-a-g-p-s-virtual-healthcare-conference)\n\n[ May 04 2023 ](/investors/press-releases/geovax-reports-2023-first-quarter-financial-results-and-provides-corporate-update)\n\n#  [ GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update ](/investors/press-releases/geovax-reports-2023-first-quarter-financial-results-and-provides-corporate-update)\n\n[ April 26 2023 ](/investors/press-releases/geovax-to-participate-in-the-4th-symposium-on-infectious-diseases-in-the-immunocompromised-host)\n\n#  [ GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host ](/investors/press-releases/geovax-to-participate-in-the-4th-symposium-on-infectious-diseases-in-the-immunocompromised-host)\n\n[ April 25 2023 ](/investors/press-releases/geovax-to-host-first-quarter-2023-business-update-and-financial-results-conference-call-on-may-4-2023)\n\n#  [ GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 ](/investors/press-releases/geovax-to-host-first-quarter-2023-business-update-and-financial-results-conference-call-on-may-4-2023)\n\n[ April 19 2023 ](/investors/press-releases/geovax-announces-expansion-of-next-generation-covid-19-vaccine-rights-to-include-omicron-variants-and-use-against-orthopoxviruses)\n\n#  [ GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses ](/investors/press-releases/geovax-announces-expansion-of-next-generation-covid-19-vaccine-rights-to-include-omicron-variants-and-use-against-orthopoxviruses)\n\n[ April 06 2023 ](/investors/press-releases/geovax-announces-presentation-of-preliminary-data-from-clinical-trial-of-next-generation-covid-19-vaccine-candidate)\n\n#  [ GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate ](/investors/press-releases/geovax-announces-presentation-of-preliminary-data-from-clinical-trial-of-next-generation-covid-19-vaccine-candidate)\n\n[ April 05 2023 ](/investors/press-releases/geovax-marburg-vaccine-data-presented-at-the-23rd-annual-world-vaccine-congress)\n\n#  [ GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress ](/investors/press-releases/geovax-marburg-vaccine-data-presented-at-the-23rd-annual-world-vaccine-congress)\n\n[ March 30 2023 ](/investors/press-releases/geovax-to-participate-at-the-world-vaccine-congress-with-multiple-presentations)\n\n#  [ GeoVax to Participate at the World Vaccine Congress with Multiple Presentations ](/investors/press-releases/geovax-to-participate-at-the-world-vaccine-congress-with-multiple-presentations)\n\n[ March 23 2023 ](/investors/press-releases/geovax-reports-2022-year-end-financial-results-and-provides-corporate-update)\n\n#  [ GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update ](/investors/press-releases/geovax-reports-2022-year-end-financial-results-and-provides-corporate-update)\n\n[ March 15 2023 ](/investors/press-releases/geovax-congratulates-don-diamond-ph-d-as-finalist-for-vaccine-industry-excellence-award-at-world-vaccine-congress)\n\n#  [ GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress ](/investors/press-releases/geovax-congratulates-don-diamond-ph-d-as-finalist-for-vaccine-industry-excellence-award-at-world-vaccine-congress)\n\n[ March 09 2023 ](/investors/press-releases/geovax-to-report-2022-financial-results-on-thursday-march-23-2023-and-provide-corporate-update)\n\n#  [ GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update ](/investors/press-releases/geovax-to-report-2022-financial-results-on-thursday-march-23-2023-and-provide-corporate-update)\n\n[ February 26 2023 ](/investors/press-releases/geovax-vaccine-data-included-in-hiv-therapy-presentation-at-the-conference-on-retroviruses-and-opportunistic-infections)\n\n#  [ GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections  ](/investors/press-releases/geovax-vaccine-data-included-in-hiv-therapy-presentation-at-the-conference-on-retroviruses-and-opportunistic-infections)\n\n[ February 15 2023 ](/investors/press-releases/geovax-and-emvenio-announce-collaboration-to-expand-phase-2-covid-19-booster-vaccine-clinical-trial)\n\n#  [ GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial ](/investors/press-releases/geovax-and-emvenio-announce-collaboration-to-expand-phase-2-covid-19-booster-vaccine-clinical-trial)\n\n[ February 08 2023 ](/investors/press-releases/geovax-announces-decisive-progress-in-establishing-high-capacity-continuous-cell-line-system-to-manufacture-mva-based-vaccines)\n\n#  [ GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines ](/investors/press-releases/geovax-announces-decisive-progress-in-establishing-high-capacity-continuous-cell-line-system-to-manufacture-mva-based-vaccines)\n\n[ February 07 2023 ](/investors/press-releases/geovax-expands-gedeptin-clinical-research-for-advanced-head-and-neck-cancers)\n\n#  [ GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers ](/investors/press-releases/geovax-expands-gedeptin-clinical-research-for-advanced-head-and-neck-cancers)\n\n[ January 26 2023 ](/investors/press-releases/geovax-to-present-at-the-2023-bio-ceo-investor-conference)\n\n#  [ GeoVax to Present at the 2023 BIO CEO & Investor Conference ](/investors/press-releases/geovax-to-present-at-the-2023-bio-ceo-investor-conference)\n\n[ January 25 2023 ](/investors/press-releases/geovax-receives-notice-of-allowance-for-zika-vaccine-patent)\n\n#  [ GeoVax Receives Notice of Allowance for Zika Vaccine Patent ](/investors/press-releases/geovax-receives-notice-of-allowance-for-zika-vaccine-patent)\n\n[ January 04 2023 ](/investors/press-releases/geovax-to-present-at-biotech-showcase-during-j-p-morgan-healthcare-week-2023)\n\n#  [ GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 ](/investors/press-releases/geovax-to-present-at-biotech-showcase-during-j-p-morgan-healthcare-week-2023)\n\n[ December 20 2022 ](/investors/press-releases/valerie-montgomery-rice-md-facog-president-and-ceo-of-morehouse-school-of-medicine-appointed-special-advisor-to-geovax)\n\n#  [ Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax ](/investors/press-releases/valerie-montgomery-rice-md-facog-president-and-ceo-of-morehouse-school-of-medicine-appointed-special-advisor-to-geovax)\n\n[ December 07 2022 ](/investors/press-releases/geovax-appoints-jayne-morgan-m-d-to-its-board-of-directors)\n\n#  [ GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors ](/investors/press-releases/geovax-appoints-jayne-morgan-m-d-to-its-board-of-directors)\n\n[ November 28 2022 ](/investors/press-releases/geovax-to-present-at-the-world-vaccine-immunotherapy-congress-west-coast-2022)\n\n#  [ GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 ](/investors/press-releases/geovax-to-present-at-the-world-vaccine-immunotherapy-congress-west-coast-2022)\n\n[ November 09 2022 ](/investors/press-releases/geovax-reports-2022-third-quarter-financial-results-and-provides-corporate-update)\n\n#  [ GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update ](/investors/press-releases/geovax-reports-2022-third-quarter-financial-results-and-provides-corporate-update)\n\n[ October 26 2022 ](/investors/press-releases/geovax-to-host-third-quarter-2022-business-update-and-financial-results-conference-call-on-november-9-2022)\n\n#  [ GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 ](/investors/press-releases/geovax-to-host-third-quarter-2022-business-update-and-financial-results-conference-call-on-november-9-2022)\n\n[ October 11 2022 ](/investors/press-releases/geovax-to-present-at-vaccines-summit-2022)\n\n#  [ GeoVax to Present at Vaccines Summit-2022 ](/investors/press-releases/geovax-to-present-at-vaccines-summit-2022)\n\n[ October 06 2022 ](/investors/press-releases/geovax-to-present-at-upcoming-investor-conferences)\n\n#  [ GeoVax to Present at Upcoming Investor Conferences ](/investors/press-releases/geovax-to-present-at-upcoming-investor-conferences)\n\n[ September 07 2022 ](/investors/press-releases/geovax-to-present-at-the-h-c-wainwright-24th-annual-global-investment-conference)\n\n#  [ GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference ](/investors/press-releases/geovax-to-present-at-the-h-c-wainwright-24th-annual-global-investment-conference)\n\n[ September 01 2022 ](/investors/press-releases/geovax-announces-addition-to-its-board-of-directors)\n\n#  [ GeoVax Announces Addition to its Board of Directors ](/investors/press-releases/geovax-announces-addition-to-its-board-of-directors)\n\n[ August 03 2022 ](/investors/press-releases/geovax-reports-2022-second-quarter-financial-results-and-provides-corporate-update)\n\n#  [ GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update ](/investors/press-releases/geovax-reports-2022-second-quarter-financial-results-and-provides-corporate-update)\n\n[ July 28 2022 ](/investors/press-releases/geovax-announces-peer-reviewed-publication-in-npj-vaccines-of-preclinical-data-for-vaccine-candidate-against-sudan-ebolavirus-showing-100-protection-with-a-single-immunization)\n\n#  [ GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization ](/investors/press-releases/geovax-announces-peer-reviewed-publication-in-npj-vaccines-of-preclinical-data-for-vaccine-candidate-against-sudan-ebolavirus-showing-100-protection-with-a-single-immunization)\n\n[ July 26 2022 ](/investors/press-releases/geovax-to-report-second-quarter-2022-financial-results-on-wednesday-august-3-2022-and-provide-corporate-update)\n\n#  [ GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update ](/investors/press-releases/geovax-to-report-second-quarter-2022-financial-results-on-wednesday-august-3-2022-and-provide-corporate-update)\n\n[ June 13 2022 ](/investors/press-releases/geovax-appoints-recognized-industry-leader-john-w-sharkey-phd-as-vice-president-business-development)\n\n#  [ GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development ](/investors/press-releases/geovax-appoints-recognized-industry-leader-john-w-sharkey-phd-as-vice-president-business-development)\n\n[ June 07 2022 ](/investors/press-releases/geovax-to-present-at-bio-international-convention-2022)\n\n#  [ GeoVax to Present at BIO International Convention 2022 ](/investors/press-releases/geovax-to-present-at-bio-international-convention-2022)\n\n[ May 25 2022 ](/investors/press-releases/geovax-announces-20-million-registered-direct-and-pipe-offerings-priced-at-a-premium-to-market-under-nasdaq-rules)\n\n#  [ GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules ](/investors/press-releases/geovax-announces-20-million-registered-direct-and-pipe-offerings-priced-at-a-premium-to-market-under-nasdaq-rules)\n\n[ May 24 2022 ](/investors/press-releases/geovax-receives-notice-of-allowance-for-cancer-vaccine-patent-in-china)\n\n#  [ GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China ](/investors/press-releases/geovax-receives-notice-of-allowance-for-cancer-vaccine-patent-in-china)\n\n[ May 04 2022 ](/investors/press-releases/geovax-announces-upcoming-presentations-at-scientific-conferences-2)\n\n#  [ GeoVax Announces Upcoming Presentations at Scientific Conferences ](/investors/press-releases/geovax-announces-upcoming-presentations-at-scientific-conferences-2)\n\n[ April 27 2022 ](/investors/press-releases/geovax-reports-2022-first-quarter-financial-results-and-provides-corporate-update)\n\n#  [ GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update ](/investors/press-releases/geovax-reports-2022-first-quarter-financial-results-and-provides-corporate-update)\n\n[ April 26 2022 ](/investors/press-releases/geovax-announces-issuance-of-malaria-vaccine-patent)\n\n#  [ GeoVax Announces Issuance of Malaria Vaccine Patent ](/investors/press-releases/geovax-announces-issuance-of-malaria-vaccine-patent)\n\n[ April 19 2022 ](/investors/press-releases/geovax-to-report-first-quarter-2022-financial-results-on-wednesday-april-27-2022-and-provide-corporate-update)\n\n#  [ GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update ](/investors/press-releases/geovax-to-report-first-quarter-2022-financial-results-on-wednesday-april-27-2022-and-provide-corporate-update)\n\n[ April 12 2022 ](/investors/press-releases/geovax-to-participate-in-expert-panel-discussion-on-pan-corona-and-universal-vaccines-at-the-world-vaccine-congress)\n\n#  [ GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress ](/investors/press-releases/geovax-to-participate-in-expert-panel-discussion-on-pan-corona-and-universal-vaccines-at-the-world-vaccine-congress)\n\n[ March 22 2022 ](/investors/press-releases/geovax-announces-issuance-of-cancer-vaccine-patent)\n\n#  [ GeoVax Announces Issuance of Cancer Vaccine Patent ](/investors/press-releases/geovax-announces-issuance-of-cancer-vaccine-patent)\n\n[ March 21 2022 ](/investors/press-releases/geovax-to-present-covid-19-vaccine-data-at-the-vaccine-summit-boston-2022)\n\n#  [ GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 ](/investors/press-releases/geovax-to-present-covid-19-vaccine-data-at-the-vaccine-summit-boston-2022)\n\n[ March 16 2022 ](/investors/press-releases/geovax-to-participate-in-maxim-group-s-2022-virtual-growth-conference)\n\n#  [ GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference ](/investors/press-releases/geovax-to-participate-in-maxim-group-s-2022-virtual-growth-conference)\n\n[ March 14 2022 ](/investors/press-releases/geovax-retains-cato-sms-to-manage-two-phase-2-covid-19-vaccine-clinical-trials)\n\n#  [ GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials ](/investors/press-releases/geovax-retains-cato-sms-to-manage-two-phase-2-covid-19-vaccine-clinical-trials)\n\n[ March 10 2022 ](/investors/press-releases/data-published-in-a-lancet-journal-on-coh04s1-a-city-of-hope-developed-covid-19-vaccine-shows-it-produced-robust-antibodies-and-t-cells-against-sars-cov-2)\n\n#  [ Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 ](/investors/press-releases/data-published-in-a-lancet-journal-on-coh04s1-a-city-of-hope-developed-covid-19-vaccine-shows-it-produced-robust-antibodies-and-t-cells-against-sars-cov-2)\n\n[ March 09 2022 ](/investors/press-releases/geovax-reports-2021-year-end-financial-results-and-provides-corporate-update)\n\n#  [ GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update ](/investors/press-releases/geovax-reports-2021-year-end-financial-results-and-provides-corporate-update)\n\n[ March 07 2022 ](/investors/press-releases/geovax-announces-key-staff-appointments)\n\n#  [ GeoVax Announces Key Staff Appointments ](/investors/press-releases/geovax-announces-key-staff-appointments)\n\n[ February 23 2022 ](/investors/press-releases/geovax-to-report-2021-financial-results-on-wednesday-march-9-2022-and-provide-corporate-update)\n\n#  [ GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update ](/investors/press-releases/geovax-to-report-2021-financial-results-on-wednesday-march-9-2022-and-provide-corporate-update)\n\n[ February 22 2022 ](/investors/press-releases/geovax-ceo-selected-as-a-recipient-of-the-2022-georgia-titan-100)\n\n#  [ GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 ](/investors/press-releases/geovax-ceo-selected-as-a-recipient-of-the-2022-georgia-titan-100)\n\n[ February 08 2022 ](/investors/press-releases/geovax-to-present-at-the-2022-bio-ceo-investor-digital-conference)\n\n#  [ GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference ](/investors/press-releases/geovax-to-present-at-the-2022-bio-ceo-investor-digital-conference)\n\n[ January 20 2022 ](/investors/press-releases/geovax-announces-closing-of-10-million-private-placement)\n\n#  [ GeoVax Announces Closing of $10 Million Private Placement ](/investors/press-releases/geovax-announces-closing-of-10-million-private-placement)\n\n[ January 14 2022 ](/investors/press-releases/geovax-announces-10-million-private-placement)\n\n#  [ GeoVax Announces $10 Million Private Placement ](/investors/press-releases/geovax-announces-10-million-private-placement)\n\n[ January 13 2022 ](/investors/press-releases/geovax-retains-cato-sms-to-manage-gedeptin-phase-1-2-clinical-trial)\n\n#  [ GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial ](/investors/press-releases/geovax-retains-cato-sms-to-manage-gedeptin-phase-1-2-clinical-trial)\n\n[ January 11 2022 ](/investors/press-releases/geovax-appoints-dr-kelly-mckee-as-chief-medical-officer)\n\n#  [ GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer ](/investors/press-releases/geovax-appoints-dr-kelly-mckee-as-chief-medical-officer)\n\n[ January 05 2022 ](/investors/press-releases/geovax-to-participate-in-upcoming-life-sciences-investor-conferences)\n\n#  [ GeoVax to Participate in Upcoming Life Sciences Investor Conferences ](/investors/press-releases/geovax-to-participate-in-upcoming-life-sciences-investor-conferences)\n\n[ January 04 2022 ](/investors/press-releases/geovax-issues-shareholder-update-letter-2)\n\n#  [ GeoVax Issues Shareholder Update Letter ](/investors/press-releases/geovax-issues-shareholder-update-letter-2)\n\n×\n\n### About GeoVax\n\n  * [ Company](/about-geovax/company \"GeoVax Company\")\n  * [ Leadership](/about-geovax/leadership)\n  * [ Board of Directors & Corporate Advisors](/about-geovax/board-of-directors-corporate-advisors)\n  * [ Scientific Advisory Board](/about-geovax/scientific-advisory-board)\n  * [ Collaborators](/about-geovax/collaborators)\n\n\n\n### Our Technology\n\n  * [ Technology](/technology \"GeoVax utilizes two robust core technology platforms\")\n  * [ MVA Technology Overview](/technology/mva-technology-overview \"Immune Responses Generated\")\n  * [ Gedeptin® Technology Overview](/technology/gedeptin-technology-overview \"Gedeptin® Technology Overview\")\n  * [ Publications](/technology/publications \"GeoVax Publications\")\n\n\n\n### Product Pipeline\n\n  * [ Pipeline Summary](/technology-pipeline/pipeline-summary \"Pipeline Summary\")\n  * [ Oncology](/technology-pipeline/oncology \"GeoVax Immuno-Oncology Programs\")\n  * [ Infectious Diseases](/technology-pipeline/infectious-diseases \"GeoVax Infectious Disease Programs\")\n\n\n\n### Investors\n\n  * [ Corporate Profile](/investors/corporate-profile \"Corporate Profile\")\n  * [ News](/investors/press-releases)\n  * [ Events & Presentations](/investors/events-presentations)\n  * [ SEC Filings](/investors/sec-filings-securities-and-exchange \"SEC Filings\")\n  * [ GeoVax Stock Information](/investors/stock-information \"GOVX Stock Information\")\n  * [ Corporate Governance](/investors/corporate-governance \"Corporate Governance\")\n  * [ Analyst Coverage](/investors/analyst-coverage \"Analyst Coverage\")\n  * [ Investor FAQ's](/investors/investor-faq-s \"Investor FAQ's\")\n\n\n\n**SUBSCRIBE FOR UPDATES FROM GEOVAX** Register to receive email alerts for GeoVax press releases\n\nSUBMIT\n\nName\n\n[](#)\n\n  * [ About Us](/about-geovax \"About GeoVax\")\n    * [ Company](/about-geovax/company \"GeoVax Company\")\n    * [ Leadership](/about-geovax/leadership \"Leadership\")\n    * [ Board of Directors & Corporate Advisors](/about-geovax/board-of-directors-corporate-advisors \"Board of Directors\")\n    * [ Scientific Advisory Board](/about-geovax/scientific-advisory-board \"Scientific Advisory Board\")\n    * [ Collaborators](/about-geovax/collaborators \"Collaborators\")\n  * [ Technology](/technology \"Our Technology\")\n    * [ MVA Technology Overview](/technology/mva-technology-overview \"MVA-VLP Technology Overview\")\n    * [ Gedeptin® Technology Overview](/technology/gedeptin-technology-overview \"Gedeptin® Technology Overview\")\n    * [ Publications](/technology/publications \"GeoVax Publications\")\n  * [ Pipeline](/technology-pipeline \"GeoVax Technology Pipeline\")\n    * [ Pipeline Summary](/technology-pipeline/pipeline-summary \"Pipeline Summary\")\n    * [ Oncology](/technology-pipeline/oncology \"GeoVax Immuno-Oncology Programs\")\n    * [ Infectious Diseases](/technology-pipeline/infectious-diseases \"GeoVax Infectious Disease Programs\")\n  * [ Clinical Trials](/clinical-trial \"Clinical Trials\")\n  * [ Investors](/investors \"Investors\")\n    * [ Corporate Profile](/investors/corporate-profile \"Corporate Profile\")\n    * [ Press Releases](/investors/press-releases)\n    * [ Media](/investors/media)\n    * [ Events & Presentations](/investors/events-presentations \"GeoVax Events\")\n    * [ SEC Filings](/investors/sec-filings-securities-and-exchange \"GeoVax SEC Filings\")\n    * [ GeoVax Stock Information](/investors/stock-information \"GOVX Stock Information\")\n    * [ Corporate Governance](/investors/corporate-governance \"Corporate Governance\")\n    * [ Analyst Coverage](/investors/analyst-coverage \"Analyst Coverage\")\n    * [ Investor FAQ's](/investors/investor-faq-s \"Investor FAQ's\")\n  * [ Careers](/careers \"Careers with GeoVax\")\n  * [ Contact](/contact-us \"Contact GeoVax\")\n\n\n\n### Search\n"
        }
      ]
    },
    {
      "section_name": "SEC Filings",
      "links": [
        {
          "title": "GeoVax SEC Filings",
          "url": "https://www.geovax.com/investors/sec-filings-securities-and-exchange",
          "content": "Accessibility Tools\n\n  * Invert colors\n  * Monochrome\n  * Dark contrast\n  * Light contrast\n  * Low saturation\n  * High saturation\n  * Highlight links\n  * Highlight headings\n  * Screen reader\n  * Read mode\n  * Content scaling 100%\n  * Font size 100%\n  * Line height 100%\n  * Letter spacing 100%\n\n\n\n  * [(678) 384-7220](tel:\\(678\\)384-7220)\n  * info@geovax.com\n\n\n  * [](https://twitter.com/geovax_news)\n  * [](https://www.youtube.com/channel/UC8n5AVvUdjFgAgGde_mA_rg)\n  * [](https://www.linkedin.com/company/2124638)\n\n\n\n[![GeoVax](/images/GeoVax_logo-bright-blue-v2-315px.png)](/index.php \"GeoVax\")\n\n[](#)\n\n  * [About Us](/about-geovax \"About GeoVax\")\n\n    * [Company](/about-geovax/company \"GeoVax Company\")\n    * [Leadership](/about-geovax/leadership \"Leadership\")\n    * [Board of Directors & Corporate Advisors](/about-geovax/board-of-directors-corporate-advisors \"Board of Directors\")\n    * [Scientific Advisory Board](/about-geovax/scientific-advisory-board \"Scientific Advisory Board\")\n    * [Collaborators](/about-geovax/collaborators \"Collaborators\")\n\n  * [Technology](/technology \"Our Technology\")\n\n    * [MVA Technology Overview](/technology/mva-technology-overview \"MVA-VLP Technology Overview\")\n    * [Gedeptin® Technology Overview](/technology/gedeptin-technology-overview \"Gedeptin® Technology Overview\")\n    * [Publications](/technology/publications \"GeoVax Publications\")\n\n  * [Pipeline](/technology-pipeline \"GeoVax Technology Pipeline\")\n\n    * [Pipeline Summary](/technology-pipeline/pipeline-summary \"Pipeline Summary\")\n    * [Oncology](/technology-pipeline/oncology \"GeoVax Immuno-Oncology Programs\")\n    * [Infectious Diseases](/technology-pipeline/infectious-diseases \"GeoVax Infectious Disease Programs\")\n\n  * [Clinical Trials](/clinical-trial \"Clinical Trials\")\n  * [Investors](/investors \"Investors\")\n\n    * [Corporate Profile](/investors/corporate-profile \"Corporate Profile\")\n    * [Press Releases](/investors/press-releases)\n    * [Media](/investors/media)\n    * [Events & Presentations](/investors/events-presentations \"GeoVax Events\")\n    * [SEC Filings](/investors/sec-filings-securities-and-exchange \"GeoVax SEC Filings\")\n    * [GeoVax Stock Information](/investors/stock-information \"GOVX Stock Information\")\n    * [Corporate Governance](/investors/corporate-governance \"Corporate Governance\")\n    * [Analyst Coverage](/investors/analyst-coverage \"Analyst Coverage\")\n    * [Investor FAQ's](/investors/investor-faq-s \"Investor FAQ's\")\n\n  * [Careers](/careers \"Careers with GeoVax\")\n  * [Contact](/contact-us \"Contact GeoVax\")\n\n\n\n## SEC Filings\n\n# SEC Filings\n\n  * [ Group by ](#)\n    * [None](https://www.geovax.com/investors/sec-filings-securities-and-exchange?group_by=0)\n    * [Year](https://www.geovax.com/investors/sec-filings-securities-and-exchange?group_by=sec_filings___Year)\n    * [Date](https://www.geovax.com/investors/sec-filings-securities-and-exchange?group_by=sec_filings___Date)\n    * [Description](https://www.geovax.com/investors/sec-filings-securities-and-exchange?group_by=sec_filings___SEC_Filing_Title)\n    * [SEC Form](https://www.geovax.com/investors/sec-filings-securities-and-exchange?group_by=sec_filings___SEC_Form)\n    * [Download Word](https://www.geovax.com/investors/sec-filings-securities-and-exchange?group_by=sec_filings___Word_Doc)\n    * [Download Excel](https://www.geovax.com/investors/sec-filings-securities-and-exchange?group_by=sec_filings___Excel_Doc)\n    * [Download PDF](https://www.geovax.com/investors/sec-filings-securities-and-exchange?group_by=sec_filings___PDF_Doc)\n\n\n\nSearch: |  [ Clear filters ](#)  \n---|---  \nYear |  All 2018 2019 2020 2021 2022 2023 2024  \nDescription |  All 8-K Additional definitive proxy soliciting materials and Rule 14(a)(12) material Annual Report Current Report General Statement of Acquisition of Beneficial Ownership Initial Ownership Report Notice of Effectiveness Other Definitive Proxy Statement Other Definitive Proxy Statements  Other Preliminary Proxy Statement Other Preliminary Proxy Statements  Post-Effective amendments for registration status Preliminary Proxy Soliciting Materials  Prospectus Prospectus Supplement  Quarterly Report Registration Statement Statement of Changes in Beneficial Ownership  \n  \n[Year](#) |  [Date](#) |  Description |  SEC Form |  Download Word |  Download Excel |  Download PDF  \n---|---|---|---|---|---|---  \nNo records   \n2024  |  11-18  |  Current Report  |  [8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774924035609/govx20241118_8k.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/206?Itemid=569 \"View\")  \n2024  |  11-13  |  Current Report  |  [8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774924034910/govx20241113_8k.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/205?Itemid=569 \"View\")  \n2024  |  11-12  |  Quarterly Report  |  [10-Q](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774924034530/govx20240930_10q.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/204?Itemid=569 \"View\")  \n2024  |  10-16  |  Current Report  |  [8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774924031364/govx20241016_8k.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/203?Itemid=569 \"View\")  \n2024  |  10-15  |  Current Report  |  [8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774924031266/govx20241014_8k.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/202?Itemid=569 \"View\")  \n2024  |  10-01  |  Current Report  |  [8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774924030377/govx20241001_8k.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/201?Itemid=569 \"View\")  \n2024  |  09-25  |  Current Report  |  [8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774924029998/govx20240924_8k.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/200?Itemid=569 \"View\")  \n2024  |  09-17  |  Current Report  |  [8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774924029372/govx20240916_8k.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/199?Itemid=569 \"View\")  \n2024  |  08-30  |  Current Report  |  [8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774924028138/govx20240829_8k.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/198?Itemid=569 \"View\")  \n2024  |  08-21  |  Current Report  |  [8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774924027483/govx20240821_8k.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/197?Itemid=569 \"View\")  \n2024  |  08-14  |  Statement of Changes in Beneficial Ownership  |  [Form 4](https://www.sec.gov/Archives/edgar/data/832489/000143774924026813/xslF345X05/rdgdoc.xml) |  [ View](/component/fabrik/details/1/185?Itemid=569 \"View\")  \n2024  |  08-14  |  Statement of Changes in Beneficial Ownership  |  [Form 4](https://www.sec.gov/Archives/edgar/data/832489/000143774924026809/xslF345X05/rdgdoc.xml) |  [ View](/component/fabrik/details/1/186?Itemid=569 \"View\")  \n2024  |  08-14  |  Statement of Changes in Beneficial Ownership  |  [Form 4](https://www.sec.gov/Archives/edgar/data/832489/000143774924026804/xslF345X05/rdgdoc.xml) |  [ View](/component/fabrik/details/1/187?Itemid=569 \"View\")  \n2024  |  08-14  |  Statement of Changes in Beneficial Ownership  |  [Form 4](https://www.sec.gov/Archives/edgar/data/832489/000143774924026802/xslF345X05/rdgdoc.xml) |  [ View](/component/fabrik/details/1/188?Itemid=569 \"View\")  \n2024  |  08-14  |  Statement of Changes in Beneficial Ownership  |  [Form 4](https://www.sec.gov/Archives/edgar/data/832489/000143774924026800/xslF345X05/rdgdoc.xml) |  [ View](/component/fabrik/details/1/189?Itemid=569 \"View\")  \n2024  |  08-14  |  Statement of Changes in Beneficial Ownership  |  [Form 4](https://www.sec.gov/Archives/edgar/data/832489/000143774924026798/xslF345X05/rdgdoc.xml) |  [ View](/component/fabrik/details/1/190?Itemid=569 \"View\")  \n2024  |  08-14  |  Statement of Changes in Beneficial Ownership  |  [Form 4](https://www.sec.gov/Archives/edgar/data/832489/000143774924026793/xslF345X05/rdgdoc.xml) |  [ View](/component/fabrik/details/1/191?Itemid=569 \"View\")  \n2024  |  08-14  |  Statement of Changes in Beneficial Ownership  |  [Form 4](https://www.sec.gov/Archives/edgar/data/832489/000143774924026788/xslF345X05/rdgdoc.xml) |  [ View](/component/fabrik/details/1/192?Itemid=569 \"View\")  \n2024  |  08-14  |  Statement of Changes in Beneficial Ownership  |  [Form 4](https://www.sec.gov/Archives/edgar/data/832489/000143774924026791/xslF345X05/rdgdoc.xml) |  [ View](/component/fabrik/details/1/193?Itemid=569 \"View\")  \n2024  |  08-14  |  Statement of Changes in Beneficial Ownership  |  [Form 4](https://www.sec.gov/Archives/edgar/data/832489/000143774924026787/xslF345X05/rdgdoc.xml) |  [ View](/component/fabrik/details/1/194?Itemid=569 \"View\")  \n2024  |  08-14  |  Statement of Changes in Beneficial Ownership  |  [Form 4](https://www.sec.gov/Archives/edgar/data/832489/000143774924026786/xslF345X05/rdgdoc.xml) |  [ View](/component/fabrik/details/1/195?Itemid=569 \"View\")  \n2024  |  08-12  |  Statement of Changes in Beneficial Ownership  |  [Form 4](https://www.sec.gov/Archives/edgar/data/832489/000143774924025953/xslF345X05/rdgdoc.xml) |  [ View](/component/fabrik/details/1/196?Itemid=569 \"View\")  \n2024  |  08-07  |  Current Report  |  [8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774924025175/govx20240806_8k.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/184?Itemid=569 \"View\")  \n2024  |  08-06  |  Quarterly Report  |  [10-Q](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774924024867/govx20240630_10q.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/183?Itemid=569 \"View\")  \n2024  |  07-12  |  Current Report  |  [8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774924022656/govx20240711_8k.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/182?Itemid=569 \"View\")  \n2024  |  06-21  |  Current Report  |  [8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774924020958/govx20240614_8k.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/181?Itemid=569 \"View\")  \n2024  |  06-18  |  Current Report  |  [8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774924020615/govx20240618_8k.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/180?Itemid=569 \"View\")  \n2024  |  05-24  |  Current Report  |  [8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774924018321/govx20240524_8k.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/179?Itemid=569 \"View\")  \n2024  |  05-23  |  Current Report  |  [8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774924018144/govx20240523_8k.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/178?Itemid=569 \"View\")  \n2024  |  05-21  |  Current Report  |  [8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774924017865/govx20240521c_8k.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/177?Itemid=569 \"View\")  \n2024  |  05-15  |  Current Report  |  [8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774924017040/govx20240514_8k.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/176?Itemid=569 \"View\")  \n2024  |  05-14  |  Quarterly Report  |  [10-Q](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774924016605/govx20240331_10q.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/175?Itemid=569 \"View\")  \n2024  |  03-11  |  Annual Report  |  [10-K/A](https://www.sec.gov/ixviewer/ix.html?doc=/Archives/edgar/data/832489/000143774924007328/govx20231231_10ka.htm) |  [ View](/component/fabrik/details/1/174?Itemid=569 \"View\")  \n2024  |  03-01  |  Current Report  |  [8-K](https://www.sec.gov/ixviewer/ix.html?doc=/Archives/edgar/data/832489/000143774924006289/govx20240228_8k.htm) |  [ View](/component/fabrik/details/1/173?Itemid=569 \"View\")  \n2024  |  02-29  |  Annual Report  |  [10-K](https://www.sec.gov/ixviewer/ix.html?doc=/Archives/edgar/data/832489/000143774924006086/govx20231231_10k.htm) |  [ View](/component/fabrik/details/1/170?Itemid=569 \"View\")  \n2024  |  02-22  |  Statement of Changes in Beneficial Ownership  |  [Form 4](https://www.sec.gov/Archives/edgar/data/832489/000143774924005209/xslF345X05/rdgdoc.xml) |  [ View](/component/fabrik/details/1/172?Itemid=569 \"View\")  \n2024  |  02-16  |  Current Report  |  [8-K](https://www.sec.gov/ixviewer/ix.html?doc=/Archives/edgar/data/832489/000143774924004557/govx20240216_8k.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/168?Itemid=569 \"View\")  \n2024  |  02-07  |  Statement of Changes in Beneficial Ownership  |  [Form 4](https://www.sec.gov/Archives/edgar/data/832489/000143774924003380/xslF345X05/rdgdoc.xml) |  [ View](/component/fabrik/details/1/171?Itemid=569 \"View\")  \n2024  |  01-31  |  Current Report  |  [8-K](https://www.sec.gov/ixviewer/ix.html?doc=/Archives/edgar/data/832489/000143774924002644/govx20240130_8k.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/169?Itemid=569 \"View\")  \n2024  |  01-16  |  Current Report  |  [8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774924001386/govx20240116_8k.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/167?Itemid=569 \"View\")  \n2023  |  12-26  |  Statement of Changes in Beneficial Ownership  |  [Form 4](https://www.sec.gov/Archives/edgar/data/832489/000143774923035306/xslF345X05/rdgdoc.xml) |  [ View](/component/fabrik/details/1/166?Itemid=569 \"View\")  \n2023  |  12-08  |  Current Report  |  [8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774923033995/govx20231207_8k.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/162?Itemid=569 \"View\")  \n2023  |  12-04  |  Current Report  |  [8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774923033444/govx20231202_8k.htm) |  [ View](/component/fabrik/details/1/161?Itemid=569 \"View\")  \n2023  |  11-17  |  Other Preliminary Proxy Statement  |  [PRE 14A](https://www.sec.gov/Archives/edgar/data/832489/000143774923032473/govx20231115_pre14a.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/160?Itemid=569 \"View\")  \n2023  |  11-09  |  Current Report  |  [8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774923031145/govx20231108_8k.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/159?Itemid=569 \"View\")  \n2023  |  11-08  |  Quarterly Report  |  [10-Q](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774923030926/govx20230930_10q.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/158?Itemid=569 \"View\")  \n2023  |  09-27  |  Statement of Changes in Beneficial Ownership  |  [Form 4](https://www.sec.gov/Archives/edgar/data/832489/000143774923026935/xslF345X05/rdgdoc.xml) |  [ View](/component/fabrik/details/1/165?Itemid=569 \"View\")  \n2023  |  08-28  |  Statement of Changes in Beneficial Ownership  |  [Form 4](https://www.sec.gov/Archives/edgar/data/832489/000143774923024763/xslF345X05/rdgdoc.xml) |  [ View](/component/fabrik/details/1/164?Itemid=569 \"View\")  \n2023  |  08-21  |  Statement of Changes in Beneficial Ownership  |  [Form 4](https://www.sec.gov/Archives/edgar/data/832489/000143774923024227/xslF345X05/rdgdoc.xml) |  [ View](/component/fabrik/details/1/157?Itemid=569 \"View\")  \n2023  |  08-14  |  Statement of Changes in Beneficial Ownership  |  [Form 4](https://www.sec.gov/Archives/edgar/data/832489/000143774923023727/xslF345X05/rdgdoc.xml) |  [ View](/component/fabrik/details/1/146?Itemid=569 \"View\")  \n2023  |  08-14  |  Statement of Changes in Beneficial Ownership  |  [Form 4](https://www.sec.gov/Archives/edgar/data/832489/000143774923023731/xslF345X05/rdgdoc.xml) |  [ View](/component/fabrik/details/1/147?Itemid=569 \"View\")  \n2023  |  08-14  |  Statement of Changes in Beneficial Ownership  |  [Form 4](https://www.sec.gov/Archives/edgar/data/832489/000143774923023733/xslF345X05/rdgdoc.xml) |  [ View](/component/fabrik/details/1/148?Itemid=569 \"View\")  \n2023  |  08-14  |  Statement of Changes in Beneficial Ownership  |  [Form 4](https://www.sec.gov/Archives/edgar/data/832489/000143774923023736/xslF345X05/rdgdoc.xml) |  [ View](/component/fabrik/details/1/149?Itemid=569 \"View\")  \n2023  |  08-14  |  Statement of Changes in Beneficial Ownership  |  [Form 4](https://www.sec.gov/Archives/edgar/data/832489/000143774923023737/xslF345X05/rdgdoc.xml) |  [ View](/component/fabrik/details/1/150?Itemid=569 \"View\")  \n2023  |  08-14  |  Statement of Changes in Beneficial Ownership  |  [Form 4](https://www.sec.gov/Archives/edgar/data/832489/000143774923023738/xslF345X05/rdgdoc.xml) |  [ View](/component/fabrik/details/1/151?Itemid=569 \"View\")  \n2023  |  08-14  |  Statement of Changes in Beneficial Ownership  |  [Form 4](https://www.sec.gov/Archives/edgar/data/832489/000143774923023739/xslF345X05/rdgdoc.xml) |  [ View](/component/fabrik/details/1/152?Itemid=569 \"View\")  \n2023  |  08-14  |  Statement of Changes in Beneficial Ownership  |  [Form 4](https://www.sec.gov/Archives/edgar/data/832489/000143774923023741/xslF345X05/rdgdoc.xml) |  [ View](/component/fabrik/details/1/153?Itemid=569 \"View\")  \n2023  |  08-14  |  Statement of Changes in Beneficial Ownership  |  [Form 4](https://www.sec.gov/Archives/edgar/data/832489/000143774923023744/xslF345X05/rdgdoc.xml) |  [ View](/component/fabrik/details/1/154?Itemid=569 \"View\")  \n2023  |  08-14  |  Statement of Changes in Beneficial Ownership  |  [Form 4](https://www.sec.gov/Archives/edgar/data/832489/000143774923023745/xslF345X05/rdgdoc.xml) |  [ View](/component/fabrik/details/1/155?Itemid=569 \"View\")  \n2023  |  08-14  |  Statement of Changes in Beneficial Ownership  |  [Form 4](https://www.sec.gov/Archives/edgar/data/832489/000143774923023746/xslF345X05/rdgdoc.xml) |  [ View](/component/fabrik/details/1/156?Itemid=569 \"View\")  \n2023  |  08-10  |  Current Report  |  [8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774923022895/govx20230809_8k.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/145?Itemid=569 \"View\")  \n2023  |  08-09  |  Quarterly Report  |  [10-Q](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774923022775/govx20230630_10q.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/144?Itemid=569 \"View\")  \n2023  |  08-02  |  Current Report  |  [8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774923021649/govx20230802_8k.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/143?Itemid=569 \"View\")  \n2023  |  07-18  |  Current Report  |  [8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774923020163/govx20230718_8k.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/141?Itemid=569 \"View\")  \n2023  |  07-18  |  Prospectus  |  [424B5](https://www.sec.gov/Archives/edgar/data/832489/000143774923020154/govx20230717_424b5.htm) |  [ View](/component/fabrik/details/1/142?Itemid=569 \"View\")  \n2023  |  06-12  |  Current Report  |  [8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774923017081/govx20230610_8k.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/139?Itemid=569 \"View\")  \n2023  |  06-12  |  Other Definitive Proxy Statement  |  [DEF 14A](https://www.sec.gov/Archives/edgar/data/832489/000143774923017122/govx20230518_def14a.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/140?Itemid=569 \"View\")  \n2023  |  05-05  |  Current Report  |  [8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774923012679/govx20230503_8k.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/138?Itemid=569 \"View\")  \n2023  |  05-04  |  Quarterly Report  |  [10-Q](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774923012551/govx20230331_10q.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/137?Itemid=569 \"View\")  \n2023  |  04-27  |  Annual Report  |  [10-K/A](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774923011369/govx20221231_10ka.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/136?Itemid=569 \"View\")  \n2023  |  03-24  |  Current Report  |  [8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774923007711/govx20230323_8k.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/135?Itemid=569 \"View\")  \n2023  |  03-23  |  Annual Report  |  [10-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774923007636/govx20221231_10k.htm) |  [ View](/component/fabrik/details/1/134?Itemid=569 \"View\")  \n2022  |  12-09  |  Current Report  |  [8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774922028813/govx20221209_8k.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/133?Itemid=569 \"View\")  \n2022  |  12-08  |  Current Report  |  [8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774922028740/govx20221207_8k.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/132?Itemid=569 \"View\")  \n2022  |  11-14  |  Current Report  |  [8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774922027003/govx20221109_8k.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/131?Itemid=569 \"View\")  \n2022  |  11-09  |  Quarterly Report  |  [10-Q](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774922026579/govx20220930_10q.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/127?Itemid=569 \"View\")  \n2022  |  11-09  |  Prospectus  |  [424B3](https://www.sec.gov/Archives/edgar/data/832489/000143774922026582/govx20221107c_424b3.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/130?Itemid=569 \"View\")  \n2022  |  01-20  |  Current Report  |  [8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774922001326/govx20220118_8k.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/97?Itemid=569 \"View\")  \n2022  |  01-04  |  Current Report  |  [8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774922000309/govx20220103_8k.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/96?Itemid=569 \"View\")  \n2022  |  11-09  |  Prospectus  |  [424B3](https://www.sec.gov/Archives/edgar/data/832489/000143774922026588/0001437749-22-026588-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/128?Itemid=569 \"View\")  \n2022  |  11-09  |  Prospectus  |  [424B3](https://www.sec.gov/Archives/edgar/data/832489/000143774922026583/0001437749-22-026583-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/129?Itemid=569 \"View\")  \n2022  |  09-06  |  Initial Ownership Report  |  [Form 3](https://www.sec.gov/Archives/edgar/data/0000832489/000143774922021880/xslF345X02/rdgdoc.xml) |  [ View](/component/fabrik/details/1/124?Itemid=569 \"View\")  \n2022  |  09-01  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774922021687/0001437749-22-021687-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/122?Itemid=569 \"View\")  \n2022  |  09-01  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774922021688/0001437749-22-021688-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/123?Itemid=569 \"View\")  \n2022  |  08-04  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774922018883/0001437749-22-018883-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/121?Itemid=569 \"View\")  \n2022  |  08-03  |  Quarterly Report  |  [10-Q](https://www.sec.gov/Archives/edgar/data/832489/000143774922018639/0001437749-22-018639-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/117?Itemid=569 \"View\")  \n2022  |  08-03  |  Prospectus  |  [424B3](https://www.sec.gov/Archives/edgar/data/832489/000143774922018643/0001437749-22-018643-index.htm) |  [ View](/component/fabrik/details/1/118?Itemid=569 \"View\")  \n2022  |  08-03  |  Prospectus  |  [424B3](https://www.sec.gov/Archives/edgar/data/832489/000143774922018644/0001437749-22-018644-index.htm) |  [ View](/component/fabrik/details/1/119?Itemid=569 \"View\")  \n2022  |  08-03  |  Prospectus  |  [424B3](https://www.sec.gov/Archives/edgar/data/832489/000143774922018645/0001437749-22-018645-index.htm) |  [ View](/component/fabrik/details/1/120?Itemid=569 \"View\")  \n2022  |  07-01  |  Statement of Changes in Beneficial Ownership  |  [Form 4](https://www.sec.gov/Archives/edgar/data/832489/000143774922016567/xslF345X03/rdgdoc.xml) |  [ View](/component/fabrik/details/1/125?Itemid=569 \"View\")  \n2022  |  06-27  |  Prospectus  |  [424B3](https://www.sec.gov/Archives/edgar/data/0000832489/000143774922015940/govx20220622_424b3.htm) |  [ View](/component/fabrik/details/1/116?Itemid=569 \"View\")  \n2022  |  06-27  |  Statement of Changes in Beneficial Ownership  |  [Form 4](https://www.sec.gov/Archives/edgar/data/0000832489/000143774922016072/xslF345X03/rdgdoc.xml) |  [ View](/component/fabrik/details/1/126?Itemid=569 \"View\")  \n2022  |  06-14  |  Registration Statement  |  [S-1](https://www.sec.gov/Archives/edgar/data/832489/000143774922014947/0001437749-22-014947-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/115?Itemid=569 \"View\")  \n2022  |  06-13  |  Other Definitive Proxy Statement  |  [DEF 14A](https://www.sec.gov/Archives/edgar/data/832489/000143774922014894/0001437749-22-014894-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/114?Itemid=569 \"View\")  \n2022  |  05-27  |  Prospectus  |  [424B5](https://www.sec.gov/Archives/edgar/data/832489/000143774922013739/govx20220526_424b5.htm) |  [ View](/component/fabrik/details/1/111?Itemid=569 \"View\")  \n2022  |  05-27  |  Current Report  |  [8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774922013800/govx20220526_8k.htm) |  [ View](/component/fabrik/details/1/112?Itemid=569 \"View\")  \n2022  |  05-27  |  Other Preliminary Proxy Statements  |  [PRE 14A](https://www.sec.gov/Archives/edgar/data/832489/000143774922013803/govx20220525_pre14a.htm) |  [ View](/component/fabrik/details/1/113?Itemid=569 \"View\")  \n2022  |  05-02  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774922010332/0001437749-22-010332-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/110?Itemid=569 \"View\")  \n2022  |  04-27  |  Quarterly Report  |  [10-Q](https://www.sec.gov/Archives/edgar/data/832489/000143774922009862/0001437749-22-009862-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/104?Itemid=569 \"View\")  \n2022  |  04-27  |  Current Report  |  [10-K/A](https://www.sec.gov/Archives/edgar/data/832489/000143774922009865/0001437749-22-009865-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/105?Itemid=569 \"View\")  \n2022  |  04-27  |  Prospectus  |  [424B3](https://www.sec.gov/Archives/edgar/data/832489/000143774922009867/0001437749-22-009867-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/108?Itemid=569 \"View\")  \n2022  |  04-27  |  Prospectus  |  [424B3](https://www.sec.gov/Archives/edgar/data/832489/000143774922009866/0001437749-22-009866-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/109?Itemid=569 \"View\")  \n2022  |  03-10  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774922005881/0001437749-22-005881-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/103?Itemid=569 \"View\")  \n2022  |  03-09  |  Annual Report  |  [10-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/0000832489/000143774922005677/govx20211231_10k.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/100?Itemid=569 \"View\")  \n2022  |  03-09  |  Registration Statement  |  [POA No. 1 to Form S-1](https://www.sec.gov/Archives/edgar/data/0000832489/000143774922005763/govx20220301_posam.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/101?Itemid=569 \"View\")  \n2022  |  03-09  |  Registration Statement  |  [POA No. 2 to Form S-1](https://www.sec.gov/Archives/edgar/data/0000832489/000143774922005764/govx20220301b_posam.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/102?Itemid=569 \"View\")  \n2022  |  02-11  |  Prospectus  |  [424B3](https://www.sec.gov/Archives/edgar/data/832489/000143774922003074/0001437749-22-003074-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/99?Itemid=569 \"View\")  \n2022  |  02-04  |  Registration Statement  |  [S-1](https://www.sec.gov/Archives/edgar/data/832489/000143774922002516/0001437749-22-002516-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/98?Itemid=569 \"View\")  \n2021  |  03-23  |  Registration Statement  |  [S-1](https://www.sec.gov/ix?doc=/Archives/edgar/data/0000832489/000143774921006907/govx20210319_s1a.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/79?Itemid=569 \"View\")  \n2021  |  12-15  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774921028662/0001437749-21-028662-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/95?Itemid=569 \"View\")  \n2021  |  11-12  |  Quarterly Report  |  [10-Q](https://www.sec.gov/Archives/edgar/data/832489/000143774921026298/0001437749-21-026298-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/92?Itemid=569 \"View\")  \n2021  |  11-12  |  Prospectus  |  [424B3](https://www.sec.gov/Archives/edgar/data/832489/000143774921026299/0001437749-21-026299-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/93?Itemid=569 \"View\")  \n2021  |  11-12  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774921026407/0001437749-21-026407-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/94?Itemid=569 \"View\")  \n2021  |  11-10  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774921026180/0001437749-21-026180-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/91?Itemid=569 \"View\")  \n2021  |  09-30  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774921022929/0001437749-21-022929-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/90?Itemid=569 \"View\")  \n2021  |  09-29  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774921022842/0001437749-21-022842-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/89?Itemid=569 \"View\")  \n2021  |  08-20  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774921020569/0001437749-21-020569-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/88?Itemid=569 \"View\")  \n2021  |  08-11  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774921019476/govx20210811_8k.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/85?Itemid=569 \"View\")  \n2021  |  08-11  |  Quarterly Report  |  [10-Q](https://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774921019478/govx20210630_10q.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/86?Itemid=569 \"View\")  \n2021  |  08-11  |  Prospectus Supplement  |  [424B3](https://www.sec.gov/Archives/edgar/data/832489/000143774921019483/govx20210810_424b3.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/87?Itemid=569 \"View\")  \n2021  |  06-21  |  Other Definitive Proxy Statement  |  [DEF 14A](https://www.sec.gov/Archives/edgar/data/0000832489/000143774921015127/govx20210610_def14a.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/84?Itemid=569 \"View\")  \n2021  |  05-07  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774921011267/0001437749-21-011267-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/83?Itemid=569 \"View\")  \n2021  |  05-06  |  Quarterly Report  |  [10-Q](https://www.sec.gov/Archives/edgar/data/832489/000143774921011130/0001437749-21-011130-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/81?Itemid=569 \"View\")  \n2021  |  05-06  |  Prospectus  |  [424B3](https://www.sec.gov/Archives/edgar/data/832489/000143774921011136/0001437749-21-011136-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/82?Itemid=569 \"View\")  \n2021  |  04-28  |  Annual Report  |  [10-K/A](https://www.sec.gov/Archives/edgar/data/832489/000143774921010047/0001437749-21-010047-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/80?Itemid=569 \"View\")  \n2021  |  03-23  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/0000832489/000143774921006909/govx20210323_8k.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/77?Itemid=569 \"View\")  \n2021  |  03-23  |  Annual Report  |  [10-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/0000832489/000143774921006906/govx20201118_10k.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/78?Itemid=569 \"View\")  \n2021  |  02-11  |  Prospectus  |  [424B5](https://www.sec.gov/Archives/edgar/data/832489/000143774921002515/0001437749-21-002515-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/74?Itemid=569 \"View\")  \n2021  |  02-11  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774921002520/0001437749-21-002520-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/75?Itemid=569 \"View\")  \n2021  |  02-11  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774921002572/0001437749-21-002572-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/76?Itemid=569 \"View\")  \n2020  |  11-30  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774920024573/0001437749-20-024573-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/73?Itemid=569 \"View\")  \n2020  |  11-05  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774920022822/0001437749-20-022822-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/70?Itemid=569 \"View\")  \n2020  |  11-05  |  Quarterly Report  |  [10-Q](https://www.sec.gov/Archives/edgar/data/832489/000143774920022819/0001437749-20-022819-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/71?Itemid=569 \"View\")  \n2020  |  11-05  |  Prospectus  |  [424B3](https://www.sec.gov/Archives/edgar/data/832489/000143774920022820/0001437749-20-022820-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/72?Itemid=569 \"View\")  \n2020  |  10-26  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774920021652/0001437749-20-021652-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/69?Itemid=569 \"View\")  \n2020  |  09-29  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774920020446/0001437749-20-020446-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/68?Itemid=569 \"View\")  \n2020  |  09-25  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774920020279/0001437749-20-020279-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/67?Itemid=569 \"View\")  \n2020  |  08-10  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774920017218/0001437749-20-017218-index.htm) |  [![](https://www.geovax.com/media/com_fabrik/images/doc.png)](https://www.geovax.com/images/stories/uploads/Form_8-K_-_8-7-20_-_Ann_Mtg.DOCX \"https://www.geovax.com/images/stories/uploads/Form_8-K_-_8-7-20_-_Ann_Mtg.DOCX\") |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/64?Itemid=569 \"View\")  \n2020  |  08-10  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774920017276/0001437749-20-017276-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/65?Itemid=569 \"View\")  \n2020  |  08-10  |  Quarterly Report  |  [10-Q](https://www.sec.gov/Archives/edgar/data/832489/000143774920017250/0001437749-20-017250-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/66?Itemid=569 \"View\")  \n2020  |  07-07  |  Other Definitive Proxy Statement  |  [DEF 14A](https://www.sec.gov/Archives/edgar/data/832489/000143774920014682/0001437749-20-014682-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/62?Itemid=569 \"View\")  \n2020  |  07-07  |  Additional definitive proxy soliciting materials and Rule 14(a)(12) material  |  [DEFA 14](https://www.sec.gov/Archives/edgar/data/832489/000143774920014684/0001437749-20-014684-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/63?Itemid=569 \"View\")  \n2020  |  06-26  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774920014012/0001437749-20-014012-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/61?Itemid=569 \"View\")  \n2020  |  06-25  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774920013883/0001437749-20-013883-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/60?Itemid=569 \"View\")  \n2020  |  05-22  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774920011667/0001437749-20-011667-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/59?Itemid=569 \"View\")  \n2020  |  05-06  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774920009625/0001437749-20-009625-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/58?Itemid=569 \"View\")  \n2020  |  05-05  |  Quarterly Report  |  [10-Q](https://www.sec.gov/Archives/edgar/data/832489/000143774920009452/0001437749-20-009452-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/57?Itemid=569 \"View\")  \n2020  |  04-28  |  Annual Report  |  [10-K/A](https://www.sec.gov/Archives/edgar/data/832489/000143774920008710/0001437749-20-008710-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/56?Itemid=569 \"View\")  \n2020  |  04-20  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774920008037/0001437749-20-008037-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/55?Itemid=569 \"View\")  \n2020  |  03-25  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774920006096/0001437749-20-006096-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/54?Itemid=569 \"View\")  \n2020  |  03-24  |  Annual Report  |  [10-K](https://www.sec.gov/Archives/edgar/data/832489/000143774920006029/0001437749-20-006029-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/53?Itemid=569 \"View\")  \n2020  |  03-09  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774920004609/0001437749-20-004609-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/52?Itemid=569 \"View\")  \n2020  |  01-24  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774920001117/0001437749-20-001117-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/51?Itemid=569 \"View\")  \n2020  |  01-23  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774920000912/0001437749-20-000912-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/50?Itemid=569 \"View\")  \n2020  |  01-03  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774920000144/0001437749-20-000144-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/49?Itemid=569 \"View\")  \n2019  |  11-14  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774919022969/0001437749-19-022969-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/48?Itemid=569 \"View\")  \n2019  |  11-07  |  Quarterly Report  |  [10-Q](https://www.sec.gov/Archives/edgar/data/832489/000143774919021977/0001437749-19-021977-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/46?Itemid=569 \"View\")  \n2019  |  11-07  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774919021959/0001437749-19-021959-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/47?Itemid=569 \"View\")  \n2019  |  11-01  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774919021130/0001437749-19-021130-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/45?Itemid=569 \"View\")  \n2019  |  10-18  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774919020245/0001437749-19-020245-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/44?Itemid=569 \"View\")  \n2019  |  10-07  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774919019751/0001437749-19-019751-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/43?Itemid=569 \"View\")  \n2019  |  10-01  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774919019306/0001437749-19-019306-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/42?Itemid=569 \"View\")  \n2019  |  08-15  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774919016785/0001437749-19-016785-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/35?Itemid=569 \"View\")  \n2019  |  08-13  |  Quarterly Report  |  [10-Q](https://www.sec.gov/Archives/edgar/data/832489/000143774919016606/0001437749-19-016606-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/36?Itemid=569 \"View\")  \n2019  |  08-02  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774919015304/0001437749-19-015304-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/37?Itemid=569 \"View\")  \n2019  |  07-24  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774919014546/0001437749-19-014546-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/38?Itemid=569 \"View\")  \n2019  |  07-17  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774919014110/0001437749-19-014110-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/39?Itemid=569 \"View\")  \n2019  |  06-19  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774919012298/0001437749-19-012298-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/15?Itemid=569 \"View\")  \n2019  |  05-14  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774919009854/0001437749-19-009854-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/4?Itemid=569 \"View\")  \n2019  |  05-13  |  Quarterly Report  |  [10-Q](https://www.sec.gov/Archives/edgar/data/832489/000143774919009674/0001437749-19-009674-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/5?Itemid=569 \"View\")  \n2019  |  04-30  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774919008334/0001437749-19-008334-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/6?Itemid=569 \"View\")  \n2019  |  04-26  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774919008037/0001437749-19-008037-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/7?Itemid=569 \"View\")  \n2019  |  04-15  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774919007190/0001437749-19-007190-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/14?Itemid=569 \"View\")  \n2019  |  04-12  |  Annual Report  |  [10-K/A](https://www.sec.gov/Archives/edgar/data/832489/000143774919007104/0001437749-19-007104-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/13?Itemid=569 \"View\")  \n2019  |  03-27  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774919005796/0001437749-19-005796-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/40?Itemid=569 \"View\")  \n2019  |  03-26  |  Annual Report  |  [10-K](https://www.sec.gov/Archives/edgar/data/832489/000143774919005682/0001437749-19-005682-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/41?Itemid=569 \"View\")  \n2019  |  03-14  |  Other Definitive Proxy Statements  |  [DEF 14A](https://www.sec.gov/Archives/edgar/data/832489/000143774919004867/0001437749-19-004867-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  [ View](/component/fabrik/details/1/2?Itemid=569 \"View\")  \n2019  |  03-01  |  Other Definitive Proxy Statements  |  [DEF 14A](https://www.sec.gov/Archives/edgar/data/832489/000143774919003772/0001437749-19-003772-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/3?Itemid=569 \"View\")  \n2019  |  02-27  |  Preliminary Proxy Soliciting Materials  |  [PRER14A](https://www.sec.gov/Archives/edgar/data/832489/000143774919003499/0001437749-19-003499-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/8?Itemid=569 \"View\")  \n2019  |  02-26  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774919003336/0001437749-19-003336-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/9?Itemid=569 \"View\")  \n2019  |  02-19  |  8-K  |  [Current Report](https://www.sec.gov/Archives/edgar/data/832489/000143774919002800/govx20190218_8k.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/10?Itemid=569 \"View\")  \n2019  |  02-19  |  Other Preliminary Proxy Statements  |  [PRE14A](https://www.sec.gov/Archives/edgar/data/832489/000143774919002804/govx20190215_pre14a.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/11?Itemid=569 \"View\")  \n2019  |  01-22  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774919001164/0001437749-19-001164-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/12?Itemid=569 \"View\")  \n2018  |  12-27  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774918022697/govx20181227_8k.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/34?Itemid=569 \"View\")  \n2018  |  03-23  |  Annual Report  |  [10-K](https://www.sec.gov/Archives/edgar/data/832489/000143774918005301/govx20171231_10k.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/17?Itemid=569 \"View\")  \n2018  |  03-23  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774918005332/govx20180322_8k.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/18?Itemid=569 \"View\")  \n2018  |  03-23  |  Post-Effective amendments for registration status  |  [POS AM](https://www.sec.gov/Archives/edgar/data/832489/000143774918005334/govx20180314_posam.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/19?Itemid=569 \"View\")  \n2018  |  11-08  |  Quarterly Report  |  [10-Q](https://www.sec.gov/Archives/edgar/data/832489/000143774918020037/0001437749-18-020037-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/31?Itemid=569 \"View\")  \n2018  |  11-08  |  Prospectus  |  [424B3](https://www.sec.gov/Archives/edgar/data/832489/000143774918020045/0001437749-18-020045-index.htm) |  [ View](/component/fabrik/details/1/32?Itemid=569 \"View\")  \n2018  |  09-07  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774918016713/0001437749-18-016713-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/30?Itemid=569 \"View\")  \n2018  |  08-07  |  Quarterly Report  |  [10-Q](https://www.sec.gov/Archives/edgar/data/832489/000143774918014749/0001437749-18-014749-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/27?Itemid=569 \"View\")  \n2018  |  08-07  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774918014721/0001437749-18-014721-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/28?Itemid=569 \"View\")  \n2018  |  08-07  |  Prospectus  |  [424B3](https://www.sec.gov/Archives/edgar/data/832489/000143774918014752/0001437749-18-014752-index.htm) |  [ View](/component/fabrik/details/1/29?Itemid=569 \"View\")  \n2018  |  06-15  |  Current Report  |  [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774918011884/0001437749-18-011884-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/26?Itemid=569 \"View\")  \n2018  |  05-03  |  Quarterly Report  |  [10-Q](https://www.sec.gov/Archives/edgar/data/832489/000143774918008476/0001437749-18-008476-index.htm) |  ![](https://www.geovax.com/media/com_fabrik/images/doc.png) |  ![](https://www.geovax.com/media/com_fabrik/images/pdf.png) |  [ View](/component/fabrik/details/1/24?Itemid=569 \"View\")  \n2018  |  05-03  |  Prospectus  |  [424B3](https://www.sec.gov/Archives/edgar/data/832489/000143774918008477/0001437749-18-008477-index.htm) |  [ View](/component/fabrik/details/1/25?Itemid=569 \"View\")  \n2018  |  04-27  |  Additional definitive proxy soliciting materials and Rule 14(a)(12) material  |  [DEFA14A](https://www.sec.gov/Archives/edgar/data/832489/000143774918007920/0001437749-18-007920-index.htm) |  [ View](/component/fabrik/details/1/23?Itemid=569 \"View\")  \n2018  |  04-27  |  Other definitive proxy statements  |  [def 14a](https://www.sec.gov/Archives/edgar/data/832489/000143774918007919/0001437749-18-007919-index.htm) |  [ View](/component/fabrik/details/1/33?Itemid=569 \"View\")  \n2018  |  04-03  |  Notice of Effectiveness  |  [EFFECT](https://www.sec.gov/Archives/edgar/data/832489/999999999518000730/9999999995-18-000730-index.htm) |  [ View](/component/fabrik/details/1/21?Itemid=569 \"View\")  \n2018  |  04-03  |  Prospectus  |  [424B1](https://www.sec.gov/Archives/edgar/data/832489/000143774918006125/0001437749-18-006125-index.htm) |  [ View](/component/fabrik/details/1/22?Itemid=569 \"View\")  \n2018  |  03-29  |  General Statement of Acquisition of Beneficial Ownership  |  [SC 13D/A](https://www.sec.gov/Archives/edgar/data/832489/000137763518000003/0001377635-18-000003-index.htm) |  [ View](/component/fabrik/details/1/20?Itemid=569 \"View\")  \n[ View](/component/fabrik/details/1/163?Itemid=569 \"View\")  \n  \n### About GeoVax\n\n  * [ Company](/about-geovax/company \"GeoVax Company\")\n  * [ Leadership](/about-geovax/leadership)\n  * [ Board of Directors & Corporate Advisors](/about-geovax/board-of-directors-corporate-advisors)\n  * [ Scientific Advisory Board](/about-geovax/scientific-advisory-board)\n  * [ Collaborators](/about-geovax/collaborators)\n\n\n\n### Our Technology\n\n  * [ Technology](/technology \"GeoVax utilizes two robust core technology platforms\")\n  * [ MVA Technology Overview](/technology/mva-technology-overview \"Immune Responses Generated\")\n  * [ Gedeptin® Technology Overview](/technology/gedeptin-technology-overview \"Gedeptin® Technology Overview\")\n  * [ Publications](/technology/publications \"GeoVax Publications\")\n\n\n\n### Product Pipeline\n\n  * [ Pipeline Summary](/technology-pipeline/pipeline-summary \"Pipeline Summary\")\n  * [ Oncology](/technology-pipeline/oncology \"GeoVax Immuno-Oncology Programs\")\n  * [ Infectious Diseases](/technology-pipeline/infectious-diseases \"GeoVax Infectious Disease Programs\")\n\n\n\n### Investors\n\n  * [ Corporate Profile](/investors/corporate-profile \"Corporate Profile\")\n  * [ News](/investors/press-releases)\n  * [ Events & Presentations](/investors/events-presentations)\n  * [ SEC Filings](/investors/sec-filings-securities-and-exchange \"SEC Filings\")\n  * [ GeoVax Stock Information](/investors/stock-information \"GOVX Stock Information\")\n  * [ Corporate Governance](/investors/corporate-governance \"Corporate Governance\")\n  * [ Analyst Coverage](/investors/analyst-coverage \"Analyst Coverage\")\n  * [ Investor FAQ's](/investors/investor-faq-s \"Investor FAQ's\")\n\n\n\n**SUBSCRIBE FOR UPDATES FROM GEOVAX** Register to receive email alerts for GeoVax press releases\n\nSUBMIT\n\nFirst Name\n\n[](#)\n\n  * [ About Us](/about-geovax \"About GeoVax\")\n    * [ Company](/about-geovax/company \"GeoVax Company\")\n    * [ Leadership](/about-geovax/leadership \"Leadership\")\n    * [ Board of Directors & Corporate Advisors](/about-geovax/board-of-directors-corporate-advisors \"Board of Directors\")\n    * [ Scientific Advisory Board](/about-geovax/scientific-advisory-board \"Scientific Advisory Board\")\n    * [ Collaborators](/about-geovax/collaborators \"Collaborators\")\n  * [ Technology](/technology \"Our Technology\")\n    * [ MVA Technology Overview](/technology/mva-technology-overview \"MVA-VLP Technology Overview\")\n    * [ Gedeptin® Technology Overview](/technology/gedeptin-technology-overview \"Gedeptin® Technology Overview\")\n    * [ Publications](/technology/publications \"GeoVax Publications\")\n  * [ Pipeline](/technology-pipeline \"GeoVax Technology Pipeline\")\n    * [ Pipeline Summary](/technology-pipeline/pipeline-summary \"Pipeline Summary\")\n    * [ Oncology](/technology-pipeline/oncology \"GeoVax Immuno-Oncology Programs\")\n    * [ Infectious Diseases](/technology-pipeline/infectious-diseases \"GeoVax Infectious Disease Programs\")\n  * [ Clinical Trials](/clinical-trial \"Clinical Trials\")\n  * [ Investors](/investors \"Investors\")\n    * [ Corporate Profile](/investors/corporate-profile \"Corporate Profile\")\n    * [ Press Releases](/investors/press-releases)\n    * [ Media](/investors/media)\n    * [ Events & Presentations](/investors/events-presentations \"GeoVax Events\")\n    * [ SEC Filings](/investors/sec-filings-securities-and-exchange \"GeoVax SEC Filings\")\n    * [ GeoVax Stock Information](/investors/stock-information \"GOVX Stock Information\")\n    * [ Corporate Governance](/investors/corporate-governance \"Corporate Governance\")\n    * [ Analyst Coverage](/investors/analyst-coverage \"Analyst Coverage\")\n    * [ Investor FAQ's](/investors/investor-faq-s \"Investor FAQ's\")\n  * [ Careers](/careers \"Careers with GeoVax\")\n  * [ Contact](/contact-us \"Contact GeoVax\")\n\n\n\n### Search\n"
        }
      ]
    }
  ]
}